ÃÛÌÒÊÓÆµ

Life Sciences

  • July 25, 2025

    NGM Biopharma Investors Take $6M Deal To End Sale Suit

    The Column Group and former stockholders of NGM Biopharmaceuticals have agreed to settle for $6 million a Delaware Court of Chancery lawsuit challenging NGM's $135 million, $1.55-per-share sale to The Column Group, its pre-deal venture capital controller.

  • July 25, 2025

    Fed. Circ. Punts $17M Drug Arbitration Case To 2nd Circ.

    The Federal Circuit said Friday it lacked jurisdiction over a dispute over a $16.6 million arbitral award between two drugmakers, ruling that because it was being asked to consider an arbitration issue and not a patent law issue, the Second Circuit must hear the case.

  • July 25, 2025

    Health Data Co. Investor Fraud Suit Headed To Mediation

    The parties in a putative class action claiming a healthcare technology company misled investors about a data platform it claimed to operate, but which didn't actually exist, told a Connecticut federal court that they "agree this case is well suited for mediation."

  • July 25, 2025

    1st Circ. Backs Ex-Pharma Director's $24M Disability Bias Win

    The First Circuit declined to scrap a $24 million verdict for a former lab director of a Thermo Fisher Scientific Inc. subsidiary who claimed she was fired for seeking alternative public speaking arrangements due to her anxiety, ruling the evidence presented supported the jury's verdict.

  • July 25, 2025

    Boutique Upadhye Tang Gets McDermott Life Sciences Partner

    A six-year veteran of McDermott Will & Emery LLP's Washington, D.C., team has moved his pharmaceutical patent litigation practice to Upadhye Tang LLP, a boutique that focuses on intellectual property and U.S. Food and Drug Administration matters.

  • July 24, 2025

    Trump Admin Asks Justices To Stay Block On NIH Grant Cuts

    The Trump administration on Thursday urged the U.S. Supreme Court to stay a district court's preliminary injunction so that the National Institutes of Health can resume terminating $783 million in grants, saying the lower court, under a recent high court ruling, lacked jurisdiction to make the government pay the grants.

  • July 24, 2025

    Genentech Seeks Win After $122M Biogen Royalties Mistrial

    Genentech Inc. urged a California federal court Wednesday to rule that Biogen MA Inc. owes $122 million in patent royalties and interest under the "only coherent construction" of their licensing deal, in a rare post-mistrial arrangement that will see the judge step in to deliver the verdict.

  • July 24, 2025

    NC Judge Reins In Row Over Clinical Trial Software Contract

    A 6-year-old breach of contract suit got pruned on its second trip to North Carolina's business court Wednesday, with defendant Pharmaceutical Research Associates Inc. winning partial summary judgment against former PRA employee Neil Raja and the healthcare technology company he founded, Value Health Solutions Inc.

  • July 24, 2025

    Pa. Court Backs Use Of DNA From Trash In 1995 Rape Case

    The Pennsylvania Superior Court on Thursday upheld the use of a John Doe warrant and decades-delayed DNA testing to identify and convict a man in 2024 for the violent rape of a Penn State student in 1995, saying in the precedent-setting opinion that police were allowed to collect DNA evidence from the man's trash years later.

  • July 24, 2025

    Sun Pharma Settles Consumer Price Fixing Case For $200M

    Sun Pharmaceuticals has agreed to a $200 million settlement with a class of consumers who claim that the company joined other generics makers in fixing drug prices.

  • July 24, 2025

    FTC May Join Intuitive Surgical Antitrust Appeal

    The Federal Trade Commission has asked the Ninth Circuit for extra time to decide if it will weigh in on a $140 million antitrust appeal involving Intuitive Surgical's da Vinci robot.

  • July 24, 2025

    Novo Nordisk Resolves Ozempic TM Suit Against Drugmaker

    Novo Nordisk has settled claims of trademark infringement and unfair trade practices against Connecticut drugmaker LIVation LLC over the latter's comparisons of its compounded drugs to the Danish pharmaceutical company's Ozempic medication.

  • July 24, 2025

    Florida Man Gets 14 Years For $78M Drug Diversion Scheme

    The purported leader of a Florida-based operation that diverted $78 million in pharmaceutical drugs was sentenced to more than a decade in federal prison after pleading guilty to conspiracy-related charges in connection with illegally purchasing medications meant for HIV or cancer and reselling them as legitimately obtained products.

  • July 24, 2025

    Life Sciences-Focused Venture Firm Wraps $290.2M Fund

    Australian life sciences-focused venture capital firm Brandon Capital on Thursday revealed that it closed its sixth fund with AU$439 million ($290.2 million) in tow.

  • July 24, 2025

    CapVest Seeks $11.7B Stake In Stada, Plus More Rumors

    British private equity firm CapVest Partners is looking to take a major stake in German drugmaker Stada Arzneimittel in a roughly $11.7 billion deal, Comedy Central's "South Park" creators have nabbed a $1.5 billion five-year streaming rights deal with Paramount, and ExxonMobil wants to explore deepwater blocks in Trinidad and Tobago for oil and gas. Here, Law360 breaks down these and other deal rumors from the past week.

  • July 24, 2025

    3rd Circ. Rules Philly Injection Site Equals Religious 'Person'

    A nonprofit battling government resistance to its planned safe drug injection site in Philadelphia can qualify for religious freedom protections, the Third Circuit said in a precedential opinion on Thursday, reasoning the organization meets the definition of a "person" practicing religion.

  • July 24, 2025

    Eli Lilly's Trademark Suit Not 'Abuse Of Process'

    A Washington federal judge has tossed out counterclaims by a pair of clinics being sued for trademark infringement by Eli Lilly & Co., saying the acts of filing the suit and making a settlement demand are not in themselves abuse of process.

  • July 23, 2025

    NJ Fed. Judge Pulls Opinion Flagged With Nonexistent Quotes

    A New Jersey federal judge on Wednesday withdrew his decision declining to dismiss a securities class action against CorMedix Inc. after an attorney for the biopharmaceutical firm pointed out the opinion contained "a series of errors," including nonexistent quotes and misstated decisions.

  • July 23, 2025

    FTC Wants PE Firm's Medical Device Coating Deal Put On Ice

    Private equity firm GTCR BC Holdings' $627 million merger with Surmodics will bring the previously fierce competition for medical device coatings to a grinding halt, the FTC says, which is all the more reason a federal court should block the deal while an agency challenge plays out.

  • July 23, 2025

    Meta Grabs Menstrual App Users' Data For Ads, Jury Told

    Meta collected sensitive medical information using the Flo Health menstrual cycle app and used that information to sell targeted ads, a computer security expert told a California jury Wednesday in a multibillion-dollar privacy class action brought on behalf of 13 million women.

  • July 23, 2025

    Astellas, Generics Scolded For 'Abusive' Discovery In IP Case

    A Delaware federal magistrate judge on Wednesday rebuked Astellas Pharma and makers of generic drugs for what she deemed exploitation of the discovery dispute process in the brand-name company's patent infringement case, calling their dozens of fights "not just excessive" but also "abusive of the discovery dispute process."

  • July 23, 2025

    Medical Device Co. Faces Investor Suit Over Sales Decline

    Eye surgery equipment manufacturer RxSight Inc. has been hit with a proposed shareholder class action accusing it of concealing "adoption challenges" and declining sales of its products, which led to a nearly 38% hit to shares when it finally disclosed the shortcomings.

  • July 23, 2025

    Dad Pulls Suit Alleging Rehab Staffer, Teen Had 'Relationship'

    The parties in a lawsuit over an alleged sexual relationship between a Utah rehab staffer and a teenage patient have stipulated to dismissing the case from Connecticut federal court, about six months after reporting that they would try to mediate the dispute.

  • July 23, 2025

    Judge Clears Mylan On 1 Novo Nordisk Patent In Wegovy Suit

    A Delaware federal judge has found that proposed labeling for a generic version of the weight loss drug Wegovy doesn't recommend doctors prescribe it in a way covered by a Novo Nordisk patent on the brand-name treatment.

  • July 23, 2025

    Bird Marella And Bioscience Client Accused Of $87M Fraud

    An investment group that includes a "Toy Story" screenwriter is suing a Culver City, California-headquartered bioscience company and its Bird Marella attorneys in California state court, accusing them of manipulating the valuation of a company whose acquisition they funded, in order to defraud investors of $87 million.

Expert Analysis

  • Series

    Law School's Missed Lessons: Preparing For Corporate Work

    Author Photo

    Law school often doesn't cover the business strategy, financial fluency and negotiation skills needed for a successful corporate or transactional law practice, but there are practical ways to gain relevant experience and achieve the mindset shifts critical to a thriving career in this space, says Dakota Forsyth at Olshan Frome.

  • 3 Red Flags To Watch For When Valuing Patent Portfolios

    Author Photo

    As forward-looking intellectual property valuations become increasingly popular, recognizing potential concerns during the due diligence process can help develop a more accurate understanding of a portfolio's true value and potential risk, says Keegan Caldwell at Caldwell Law.

  • How Cos. Can Mitigate Increasing Microplastics Liability Risk

    Author Photo

    Amid rising scrutiny in the U.S. and Europe of microplastics' impact on health and the growing threat of litigation against consumer product and food and beverage manufacturers, companies can limit liability through compliance with labeling laws, careful contract management and other practices, say attorneys at Rogers Joseph.

  • A Cold War-Era History Lesson On Due Process

    Author Photo

    The landmark Harry Bridges case from the mid-20th century Red Scare offers important insights on why lawyers must be free of government reprisal, no matter who their client is, says Peter Afrasiabi at One LLP.

  • Series

    Improv Makes Me A Better Lawyer

    Author Photo

    Improv keeps me grounded and connected to what matters most, including in my legal career where it has helped me to maintain a balance between being analytical, precise and professional, and creative, authentic and open-minded, says Justine Gottshall at InfoLawGroup.

  • How BigLaw Executive Orders May Affect Smaller Firms

    Author Photo

    Because of the types of cases they take on, solo practitioners, small law firms and public interest attorneys may find themselves more dramatically affected by the collective impact of recent government action involving the legal industry than even the BigLaw firms named in the executive orders, says Reuben Guttman at Guttman Buschner.

  • Opinion

    Lawsuits Shouldn't Be Shadow Assets For Foreign Capital

    Author Photo

    Third-party litigation financing amplifies inefficiencies from litigation and facilitates national exposure to foreign influence in the U.S. justice system, so full disclosure of financing arrangements should be required as a matter of institutional integrity, says Roland Eisenhuth at the American Property Casualty Insurance Association.

  • How To Accelerate Your Post-Attorney Career Transition

    Author Photo

    Professionals seeking to transition to nonattorney careers may encounter skepticism as nontraditional candidates, but there are opportunities for thought leadership and to leverage speaking and writing to accelerate a post-attorney career transition, say Janet Falk at Falk Communications and Evgeny Efremkin at Toronto Metropolitan University.

  • 5 Key Licensing Considerations For AI Innovations

    Author Photo

    As businesses increasingly integrate artificial intelligence technology into their operations, they must prepare to address complex intellectual property challenges and questions surrounding licensing AI-based innovations, which require careful consideration of ownership, usage rights and regulatory compliance, says Lestin Kenton at Sterne Kessler.

  • A Higher Bar For Expert Witnesses In Drug Patent Litigation

    Author Photo

    With recent decisions emphasizing courts' growing insistence on robust methodologies in pharmaceutical patent disputes, litigators must be strategic in how they utilize expert testimony and adapt to venue-specific expectations, says Jeremy Scholem at WIT Legal.

  • Series

    Law School's Missed Lessons: Be An Indispensable Associate

    Author Photo

    While law school teaches you to research, write and think critically, it often overlooks the professional skills you will need to make yourself an essential team player when transitioning from a summer to full-time associate, say attorneys at Stinson.

  • Series

    Birding Makes Me A Better Lawyer

    Author Photo

    Observing and documenting birds in their natural habitats fosters patience, sharpens observational skills and provides moments of pure wonder — qualities that foster personal growth and enrich my legal career, says Allison Raley at Arnall Golden.

  • Series

    Adapting To Private Practice: From DOJ Leadership To BigLaw

    Author Photo

    The move from government service to private practice can feel like changing one’s identity, but as someone who has left the U.S. Department of Justice twice, I’ve learned that a successful transition requires patience, effort and the realization that the rewards of practicing law don’t come from one particular position, says Richard Donoghue at Pillsbury.

  • Fed. Circ. Ruling Reaffirms Listing Elements Separately Is Key

    Author Photo

    The Federal Circuit's decision last month in Regeneron v. Mylan reaffirms a critical principle in patent law: When a claim lists elements separately, the clear implication is that they are distinct elements, say attorneys at Taft.

  • State Extended Producer Responsibility Laws: Tips For Cos.

    Author Photo

    As states increasingly shift the onus of end-of-life product management from consumers and local governments to the businesses that produce, distribute or sell certain items, companies must track the changing landscape and evaluate the applicability of these new laws and regulations to their operations, say attorneys at Alston & Bird.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.